Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

Clicks: 2
ID: 294500
2009
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #40 of 87 articles by views in journal of leukocyte biology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Abstract TAM and other myeloid-derived tumor infiltrating cells are reviewed as pivotal players in the tumor microenvironment; implications to anti-cancer therapy are described. The microenvironment of solid tumors is characterized by a reactive stroma with an abundance of inflammatory mediators and leukocytes, dysregulated vessels and proteolytic enzymes. TAM, major players in the connection between inflammation and cancer, summarize a number of functions (e.g., promotion of tumor cell proliferation and angiogenesis, incessant matrix turnover, repression of adaptive immunity), which ultimately have an important impact on disease progression. Thus, together with other myeloid-related cells present at the tumor site (Tie2 macrophages and MDSCs), TAM represent an attractive target of novel biological therapies of tumors.
Reference Key
openalex_W2136166312 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Graziella Solinas, Giovanni Germano, Alberto Mantovani, Paola Allavena
Journal journal of leukocyte biology
Year 2009
DOI
10.1189/jlb.0609385
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.